Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys to Acquire Synomics

NEW YORK, June 21 - Accelrys announced it will acquire Synomics in a stock transaction valued at $4 million, the companies announced Thursday.

Accelrys, based in San Diego and Cambridge, UK, and a subsidiary of Pharmacopeia of Princeton, NJ, agreed to acquire all outstanding stock of privately-held Synomics. The companies believe the transaction will be completed within several days. 

"The acquisition of Synomics marks another significant step towards the development by Accelrys of a comprehensive, integrated software platform for research and development," Michael Stapleton, chief operating officer of Accelrys, said in a statement. "In addition to strengthening our strategic technology position, the acquisition will provide us with 40 highly qualified staff who will be quickly integrated, primarily into our new consulting organization."

Stapleton added that the acquisition may "slightly dilute" Accelry's earnings for the remainder of 2001 as the company integrates Synomics software into its own technology and its sales and marketing network.

Synomics, a developer of enterprise-wide software systems, is based in Cambridge, UK.

Accelrys was formed in April when Pharmacopeia merged its software subsidiaries. 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.